Integer (NYSE:ITGR) Cut to “Market Perform” at Oppenheimer

Oppenheimer downgraded shares of Integer (NYSE:ITGR) from an outperform rating to a market perform rating in a research report sent to investors on Friday, Marketbeat Ratings reports.

A number of other analysts have also weighed in on ITGR. Wells Fargo & Company reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Integer in a research report on Tuesday, December 3rd. KeyCorp raised their price objective on shares of Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Truist Financial raised their price objective on shares of Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Citigroup raised their target price on shares of Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a research report on Wednesday, December 11th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $140.00 price target (up previously from $125.00) on shares of Integer in a report on Friday, October 25th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Integer presently has a consensus rating of “Moderate Buy” and an average target price of $147.67.

Integer Price Performance

NYSE ITGR opened at $129.96 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.95 and a quick ratio of 2.09. The stock’s fifty day moving average price is $137.74 and its 200 day moving average price is $132.58. Integer has a 1 year low of $98.63 and a 1 year high of $146.36. The company has a market cap of $4.37 billion, a price-to-earnings ratio of 38.68, a PEG ratio of 1.72 and a beta of 1.13.

Integer (NYSE:ITGR) last posted its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). Integer had a net margin of 6.92% and a return on equity of 11.65%. The business had revenue of $449.50 million for the quarter, compared to analyst estimates of $446.28 million. As a group, equities research analysts forecast that Integer will post 6.01 earnings per share for the current year.

Hedge Funds Weigh In On Integer

Hedge funds have recently made changes to their positions in the business. Mather Group LLC. grew its holdings in Integer by 304.3% during the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 143 shares during the last quarter. Lee Danner & Bass Inc. acquired a new stake in Integer during the 4th quarter worth approximately $27,000. Huntington National Bank raised its holdings in Integer by 8,933.3% during the 3rd quarter. Huntington National Bank now owns 271 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 268 shares during the period. R Squared Ltd acquired a new stake in Integer during the 4th quarter worth approximately $44,000. Finally, Sterling Capital Management LLC raised its holdings in shares of Integer by 472.9% in the fourth quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 279 shares during the last quarter. Institutional investors and hedge funds own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.